Trending

aTTP

NICE okays Roche liver cancer immunotherapy, Sanofi’s rare disease drug

NICE okays Roche liver cancer immunotherapy, Sanofi’s rare disease drug

Previously-untreated patients with hepatocellular carcinoma (HCC), a common form of liver cancer, will have an immunotherapy-based treatment option

X

NICE okays Roche liver cancer immunotherapy, Sanofi’s rare disease drug

https://pharmaphorum.com/news/nice-okays-roche-liver-cancer-immunotherapy-sanofis-rare-disease-drug/

Sanofi’s rare disease drug Cablivi approved in the EU

Sanofi’s rare disease drug Cablivi approved in the EU

The European Commission has approved Sanofi’s Cablivi, the first treatment for patients with the rare blood-clotting disorder, acquired

X

Sanofi’s rare disease drug Cablivi approved in the EU

https://pharmaphorum.com/news/sanofi-cablivi-approved-europe/

After more encouraging data, Ablynx to file first drug with FDA

After more encouraging data, Ablynx to file first drug with FDA

New trial data will be included in US and EU filings

X

After more encouraging data, Ablynx to file first drug with FDA

https://pharmaphorum.com/news/ablynx-prepares-us-filing-caplacizumab-attp/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com